<DOC>
	<DOCNO>NCT01022658</DOCNO>
	<brief_summary>Vago-sympathetic activity , arterial stiffness endothelial function integrator cardiovascular risk . The aim pilot study , type 2 diabetic patient require insulin , compare effect improve glycemic control parameters 3 different insulin regimens act especially fasting post-prandial period . Non invasive exploration perform randomization 4 5 week insulin therapy , fast hour standardize breakfast .</brief_summary>
	<brief_title>INSUlin Regimens VASCular Functions</brief_title>
	<detailed_description>Vago-sympathetic activity , arterial stiffness endothelial function integrator cardiovascular risk . The effect control fast post-prandial blood glucose parameter study type 2 diabetic patient . The aim pilot study compare effect improve fast post-prandial blood glucose glycemic control 3 different insulin regimens 4 5 week , vago-sympathetic activity , arterial stiffness endothelial function . Patients recruit department Endocrinology-Diabetology-Nutrition Jean VERDIER hospital , AP-HP , department Endocrinology Metabolism AVICENNE hospital , BOBIGNY , AP-HP , France . After half day cardiovascular exploration , 42 patient randomize 3 group determine treatment follow 4-5 week : insulin therapy detemir dinner bed time , aspart meal , . Investigations perform morning 1 ) time randomisation 2 ) 4-5 week begin insulin therapy . We evaluate fast hour standardize breakfast biological metabolic parameter , arterial stiffness , endothelial function nervous autonomic system non-invasive device : Sphygmocor® , Finapres® , laser-doppler et Endopat2000® . Body composition evaluate impedance maestro BodPod® .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Consent patient Adults 30 72 year old type 2 diabetic patient least 1 year able self measure capillary blood glucose body mass index 2037 kg/m² , HbA1c 7.112 % Metformin SULFUNYREAS therapy least 2 month antihypertensive treatment dyslipidemic treatment unchanged 3 month Exclusion criterion : pregnancy antidiabetic medication previous 2 month , antihypertensive lipidlowering therapy change previous 2 month , insulin allergy , uncontrolled preproliferative proliferative diabetic retinopathy uncontrolled hypertension renal failure ( creatinin clearance &lt; 40 ml/min ) hepatocellular deficiency ( prothrombin time &lt; 70 % ) anemia peripheral occlusive arterial disease cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Insulin Therapy</keyword>
	<keyword>Vago-sympathetic activity</keyword>
	<keyword>arterial stiffness</keyword>
	<keyword>endothelial function</keyword>
</DOC>